Healthcare Economist May 23, 2024
Potentially so, argues Adam Fein of Drug Channels. There are two mechanisms for this. First, for drugs not covered in the maximum fair price negotiations, Fein argues that drugs with high list prices and large rebates would lead to more net savings compared to drugs with lower list price and rebates in part because in the Part D catastrophic phase, manufacturers pay 20% of gross drug cost...